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BACKGROUND
B-cell anomalies play a role in the pathogenesis of membranous nephropathy. 
B-cell depletion with rituximab may therefore be noninferior to treatment with 
cyclosporine for inducing and maintaining a complete or partial remission of pro-
teinuria in patients with this condition.
METHODS
We randomly assigned patients who had membranous nephropathy, proteinuria of 
at least 5 g per 24 hours, and a quantified creatinine clearance of at least 40 ml 
per minute per 1.73 m2 of body-surface area and had been receiving angiotensin-
system blockade for at least 3 months to receive intravenous rituximab (two infu-
sions, 1000 mg each, administered 14 days apart; repeated at 6 months in case of 
partial response) or oral cyclosporine (starting at a dose of 3.5 mg per kilogram 
of body weight per day for 12 months). Patients were followed for 24 months. The 
primary outcome was a composite of complete or partial remission of proteinuria 
at 24 months. Laboratory variables and safety were also assessed.
RESULTS
A total of 130 patients underwent randomization. At 12 months, 39 of 65 patients 
(60%) in the rituximab group and 34 of 65 (52%) in the cyclosporine group had a 
complete or partial remission (risk difference, 8 percentage points; 95% confidence 
interval [CI], −9 to 25; P = 0.004 for noninferiority). At 24 months, 39 patients (60%) 
in the rituximab group and 13 (20%) in the cyclosporine group had a complete or 
partial remission (risk difference, 40 percentage points; 95% CI, 25 to 55; P<0.001 for 
both noninferiority and superiority). Among patients in remission who tested positive 
for anti–phospholipase A2 receptor (PLA2R) antibodies, the decline in autoantibodies 
to anti-PLA2R was faster and of greater magnitude and duration in the rituximab 
group than in the cyclosporine group. Serious adverse events occurred in 11 patients 
(17%) in the rituximab group and in 20 (31%) in the cyclosporine group (P = 0.06).
CONCLUSIONS
Rituximab was noninferior to cyclosporine in inducing complete or partial remis-
sion of proteinuria at 12 months and was superior in maintaining proteinuria re-
mission up to 24 months. (Funded by Genentech and the Fulk Family Foundation; 
MENTOR ClinicalTrials.gov number, NCT01180036.)
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Membranous nephropathy is the leading cause of nephrotic syndrome in white adults. Spontaneous remission 
occurs in approximately 30% of affected patients, 
and among patients who continue to have ne-
phrotic syndrome, end-stage renal disease devel-
ops in 40 to 50% over a period of 10 years.1 A 
total of 70 to 80% of patients with membranous 
nephropathy have circulating autoantibodies to 
the phospholipase A2 receptor (PLA2R),
2 and 1 to 
3% have circulating antibodies to thrombospon-
din type-1 domain-containing 7A (THSD7A).3 In 
the remaining patients, the target antigen is un-
known. In patients with anti-PLA2R antibodies, 
there is a tight correlation between antibody lev-
els and disease activity, which suggests a causal 
relationship.2,4-6
Initial therapy for patients with membranous 
nephropathy is supportive7; immunosuppressive 
therapy is recommended for patients with per-
sistent nephrotic syndrome.7,8 A regimen of alter-
nating glucocorticoids and cyclophosphamide9-11 
is effective in 60 to 70% of patients but has been 
associated with clinically significant toxic effects, 
including hyperglycemia, myelosuppression, in-
fections, infertility, and cancer.12-14 Calcineurin in-
hibitors, including cyclosporine, are effective and 
are the preferred treatment for membranous 
nephropathy in the United States and Canada.15 
However, these agents are associated with a high 
incidence of relapse after discontinuation and 
with frequent side effects, including hypertension 
and nephrotoxic effects.
B-cell dysfunction plays a role in the pathogen-
esis of membranous nephropathy.16 Cyclophos-
phamide has a profound but unselective B-cell–
depleting effect, leading to a reduced production 
of nephrotoxic antibodies.17,18 More-selective B-cell 
depletion with rituximab, therefore, appears to 
be a promising approach.19 Multiple uncontrolled 
studies with rituximab have shown a reduction in 
proteinuria of 60 to 80% in the majority of pa-
tients for as long as 24 months after the initia-
tion of immunosuppressive treatment.20-23 One 
randomized trial compared rituximab with sup-
portive therapy in patients with membranous ne-
phropathy. Although there was no advantage with 
rituximab with regard to the primary outcome at 
6 months, follow-up over a period of 1 to 2 years 
showed more remissions with rituximab than with 
supportive therapy.24 We designed the Membra-
nous Nephropathy Trial of Rituximab (MENTOR) 
to investigate whether rituximab would be non-
inferior to cyclosporine in inducing and main-
taining remission of proteinuria, regardless of 
patients’ baseline anti-PLA2R status, for up to 24 
months in patients with apparent primary mem-
branous nephropathy.
Me thods
Trial Design and Oversight
This investigator-initiated, open-label, random-
ized, multicenter, noninferiority trial was con-
ducted at 22 sites in North America. As described 
previously,25 the trial was designed by the prin-
cipal investigators and supported by Genentech 
and the Fulk Family Foundation. Genentech also 
donated rituximab; cyclosporine was purchased 
at the usual market price. The funders had no 
role in the trial design or conduct; the collection, 
management, analysis, or interpretation of the 
data; or in the preparation or review of the manu-
script or the approval of the manuscript for sub-
mission. An independent data and safety monitor-
ing board oversaw the trial (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). Appropriately authorized eth-
ics committees approved the trial at all partici-
pating sites. The manuscript was drafted and 
written by the first and last authors, with input 
as appropriate from the statistical team and the 
investigators. The authors collected the data and 
vouch for the completeness and accuracy of the 
data and for the fidelity of the trial to the proto-
col (available at NEJM.org). The decision to sub-
mit the manuscript for publication was made by 
the authors.
Participants
Patients with membranous nephropathy were 
eligible if their diagnosis was confirmed by re-
nal biopsy, with the biopsy sample examined by 
light, immunofluorescence, and electron micros-
copy. Renal biopsy samples were centrally re-
viewed by the two principal investigators and two 
renal pathologists. Patients also had to be 18 to 
80 years of age, have proteinuria of more than 5 g 
per 24 hours on average in two 24-hour urine 
samples obtained within 14 days, have a decline 
of less than 50% in proteinuria despite renin–
angiotensin system blockade for at least 3 months 
before randomization, and have a stable quanti-
fied 24-hour creatinine clearance of at least 40 ml 
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per minute per 1.73 m2 of body-surface area. Full 
eligibility criteria, including histologic results 
from kidney biopsy, are provided in the Supple-
mentary Appendix.
All patients received best-practice supportive 
care that included blockers of the renin–angio-
tensin system, blood-pressure management tar-
geting a value of less than 130/80 mm Hg, di-
etary sodium restriction to less than 4 g per day, 
and dietary protein restriction to 0.8 to 1 g of 
protein per kilogram of body weight per day 
during at least the previous 3 months before 
randomization. Patients who had not received 
best-practice supportive care as part of their 
routine treatment underwent a 3-month run-in 
phase. If proteinuria remained at a level of at 
least 5 g per 24 hours and the creatinine clear-
ance was at least 40 ml per minute per 1.73 m2, 
patients were randomly assigned in a 1:1 ratio to 
receive rituximab or cyclosporine. The random-
ization schedule was computer-generated, strati-
fied according to site, blocked with randomly 
varied block sizes of two and four, and con-
cealed with the use of a Web-based, locked cen-
tral randomization system. All the patients pro-
vided written informed consent.
Interventions
Patients who were assigned to the rituximab 
group received 1000 mg of intravenous medica-
tion (Rituxan, Genentech) on days 1 and 15. If 
proteinuria was reduced from baseline by at least 
25% at 6 months but there was not complete re-
mission, a second course of rituximab was ad-
ministered regardless of the CD19+ B-cell count. 
If complete remission was observed at 6 months, 
no second course was given. If proteinuria was 
reduced by less than 25% by 6 months, the pa-
tient was considered to have treatment failure 
and no further rituximab was administered (Fig. 
S1 in the Supplementary Appendix).
Patients who were assigned to the cyclosporine 
group received dose-adjusted cyclosporine (Neoral, 
Novartis), starting at an oral dose of 3.5 mg per 
kilogram per day, divided into two equal doses 
given at 12-hour intervals. Target trough blood 
levels of cyclosporine were 125 to 175 ng per mil-
liliter.26 Blood levels were assessed every 2 weeks 
until the target trough level was reached. If com-
plete remission was observed at 6 months, cyclo-
sporine was tapered and discontinued over a 
2-month period. If proteinuria was reduced from 
baseline by less than 25% at 6 months, the pa-
tient was considered to have treatment failure 
and cyclosporine was discontinued. If protein-
uria was reduced by at least 25%, cyclosporine 
was continued for an additional 6 months. At 
the end of 12 months, cyclosporine was tapered 
by one third of the maintenance dose monthly 
and discontinued after 2 months. A persistent 
and otherwise unexplained increase in the serum 
creatinine level of more than 30% was managed 
by dose reduction as described previously.25 If the 
creatinine level did not fall to baseline values de-
spite dose reductions, cyclosporine was discon-
tinued and the patient was considered to have 
treatment failure.
Outcomes and Follow-up
The primary clinical outcome was the composite 
of complete or partial remission at 24 months. 
Secondary clinical outcomes included the com-
posite of complete or partial remission at 6, 12, 
and 18 months; complete remission at 6, 12, 18, 
and 24 months; time to treatment failure up to 
24 months; end-stage renal disease; and adverse 
events. Continuous secondary outcomes, includ-
ing anti-PLA2R levels, quality of life as assessed 
with the modified Kidney Disease Quality of Life 
Short Form (KDQOL-SF), version 1.3,27 protein-
uria, and creatinine clearance, were systematically 
recorded only up to the occurrence of treatment 
failure.
Complete remission was defined as protein-
uria of no more than 0.3 g per 24 hours and a 
serum albumin level of at least 3.5 g per decili-
ter. Partial remission was defined as a reduction 
in proteinuria of at least 50% from baseline plus 
final proteinuria between 0.3 g and 3.5 g per 24 
hours regardless of creatinine clearance or the 
serum albumin level. We defined no response as 
no reduction in proteinuria of at least 25% from 
baseline. Relapse was defined as the develop-
ment of proteinuria of more than 3.5 g per 24 
hours after a complete or partial remission. End-
stage renal disease was defined as a creatinine 
clearance of no more than 15 ml per minute, the 
initiation of dialysis, or renal transplantation. A 
list of outcomes and definitions is provided in 
the Supplementary Appendix.
The run-in phase included visits at −3 months 
and at week 0, when patients underwent ran-
domization and treatment was initiated. Subse-
quent visits for patients who had undergone ran-
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domization were scheduled at 1, 3, 6, 9, and 12 
months (treatment period) and at 18 and 24 
months (observation period). Proteinuria and 
creatinine clearance were estimated with the use 
of quantified 24-hour urine samples. Critical labo-
ratory values, including 24-hour urinary protein 
and creatinine, serum creatinine, and anti-PLA2R 
antibody levels as measured by enzyme-linked 
immunosorbent assay (ELISA),28 were assessed 
centrally (Section F in the Supplementary Appen-
dix). Patients were considered to be anti-PLA2R–
positive if the baseline antibody level was more 
than 40 U per milliliter.
Statistical Analysis
We calculated that a sample of 63 patients per 
group would provide the trial with 80% power to 
detect noninferiority regarding the primary out-
come at a one-sided alpha of 0.025 (equivalent to 
a two-sided alpha of 0.05) and a noninferiority 
margin of 15 percentage points on an absolute 
risk-difference scale, assuming that 55% of the 
patients in the rituximab group and 45% of those 
in the cyclosporine group had a complete or par-
tial remission at 24 months. The analysis of the 
primary composite outcome was performed in 
the intention-to-treat population with the use of 
a stepwise approach to control the family-wise 
type I error, first testing the noninferiority of ritux-
imab and then testing the superiority of rituximab 
if the noninferiority test was significant. An addi-
tional, prespecified noninferiority analysis of the 
primary outcome was performed in the per-pro-
tocol population. In both the intention-to-treat 
analysis and the per-protocol analysis, noninferi-
ority would be claimed if the lower limit of the 
two-sided 95% confidence interval for the risk 
difference was not below −15 percentage points. 
A noninferiority analysis of the secondary outcome 
of complete or partial remission at 12 months in 
the intention-to-treat population was prespeci-
fied in the statistical analysis plan. The analysis 
used a prespecified Bonferroni correction, which 
allowed for this outcome to be tested in addition 
to the primary outcome at a one-sided alpha 
level of 0.0125. One-sided P values for noninferi-
ority were calculated from z tests against the 
noninferiority margin, with calculation of the 
standard error in a generalized linear model.
An extended description of the statistical meth-
ods, including subgroup analyses, is provided in 
the Supplementary Appendix. Since the widths 
of 95% confidence intervals for secondary out-
comes were not adjusted for multiple comparisons, 
these intervals should not be used for inferences 
about treatment effects. All the analyses were 
performed with the use of Stata software, ver-
sion 14.2 (StataCorp).
R esult s
Patients
From March 2012 through September 2015, a 
total of 182 patients were screened, 130 were 
enrolled, and 65 were randomly assigned to each 
group (Fig. S2 in the Supplementary Appendix). 
The mean age of the patients was 52 years, 100 
patients (77%) were men, and 96 patients (74%) 
were anti-PLA2R–positive (Table 1). One patient 
who was randomly assigned to the rituximab 
group was anti-THSD7A–positive.
One patient who was assigned to the ritux-
imab group withdrew consent after randomiza-
tion and before treatment began; the remaining 
patients received at least one dose of the as-
signed intervention. A total of 2 patients (3%) in 
the rituximab group and 11 (17%) in the cyclo-
sporine group discontinued the intervention (dif-
ference, 14 percentage points; 95% confidence 
interval [CI], 4 to 24). Patients who had a de-
crease in proteinuria of less than 25% and were 
classified as having treatment failure at 6 months 
tended to have higher anti-PLA2R levels at base-
line and 6 months, were less likely to have an 
immunologic response, and had a lower serum 
albumin level at 6 months than patients who had 
a decrease in proteinuria of 25% or more (Tables 
S1 through S3 in the Supplementary Appendix). 
CD19+ B-cell counts in the rituximab group and 
serum trough cyclosporine levels in the cyclo-
sporine group are shown in Figures S3 and S4, 
respectively, in the Supplementary Appendix. Fol-
low-up was complete for 63 patients (97%) in the 
rituximab group and for 61 (94%) in the cyclospo-
rine group.
Clinical Outcomes
A total of 39 patients (60%) in the rituximab 
group and 13 (20%) in the cyclosporine group 
had a primary composite outcome of complete or 
partial remission at 24 months (risk difference, 
40 percentage points; 95% CI, 25 to 55) (Fig. 1). 
Tests for noninferiority in the intention-to-treat 
and per-protocol populations (Table S4 in the 
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Supplementary Appendix) and the subsequent test 
for superiority in the intention-to-treat population 
were all significant at a P value of less than 0.001. 
The secondary noninferiority analysis of the com-
posite of complete or partial remission at 12 
months was significant (P = 0.004). Table 2 pres-
ents data regarding the composite of complete or 
partial remission at time points from 6 months to 
24 months.
The treatment effect of rituximab as com-
pared with cyclosporine appeared to be consis-
tent across subgroups defined according to age, 
proteinuria, anti-PLA2R antibody status, and 
history of immunosuppressive therapy at base-
line. However, a test for interaction with sex in-
dicated a more pronounced benefit of rituximab 
in women than in men (P<0.001 for interaction), 
which was probably due to baseline imbalances 
in anti-PLA2R levels (Fig. S5 and Table S5 in the 
Supplementary Appendix). The interaction dis-
appeared after adjustment for anti-PLA2R levels 
at baseline (Table S6 in the Supplementary Ap-
pendix).
At 24 months, 23 patients (35%) in the ritux-
imab group and none of the patients in the cy-
closporine group had a complete remission (risk 
difference, 35 percentage points; 95% CI, 24 to 47) 
(Table S7 in the Supplementary Appendix). Of 
these patients, 18 were positive for anti-PLA2R 
antibodies at baseline and all were antibody-
negative at 24 months.
A total of 26 patients (40%) in the rituximab 
group and 52 (80%) in the cyclosporine group 
had treatment failure by 24 months (hazard ra-
tio, 0.34; 95% CI, 0.21 to 0.54) (Fig. 2). Figure S6 
in the Supplementary Appendix shows time-to-
event curves for complete or partial remission 
during the 12-month treatment period; patients 
in the cyclosporine group tended to have remis-
sion earlier, with a later catch-up in patients in 
the rituximab group. At the end of the treatment 
period, 39 patients (60%) in the rituximab group 
and 34 (52%) in the cyclosporine group had a 
complete or partial remission (hazard ratio for 
response, 0.85; 95% CI, 0.55 to 1.32). Figure S7 
in the Supplementary Appendix presents time-
to-event curves for treatment failure during the 
12-month observation period among these 39 
and 34 patients who were in remission at the 
end of treatment period. A total of 2 of the 39 
patients (5%) in the rituximab group and 21 of 
the 34 patients (62%) in the cyclosporine group 
had treatment failure during this period (hazard 
ratio, 0.05; 95% CI, 0.01 to 0.23). Table S8 in the 
Supplementary Appendix shows the cumulative 
numbers of patients with treatment failure at 
months 6 to 24, with pronounced between-group 
differences at 18 months and 24 months.
Characteristic
Rituximab 
(N = 65)
Cyclosporine 
(N = 65)
Age — yr 51.9±12.6 52.2±12.4
Male sex — no. (%) 47 (72) 53 (82)
Blood pressure — mm Hg
Systolic 125.7±14.8 123.3±13.4
Diastolic 74.7±10.1 76.5±9.8
Height — m 1.7±0.1 1.7±0.1
Weight — kg 96±23 90±20
Body‑mass index† 31.8±6.3 29.3±5.6
History of immunosuppressive  
therapy — no. (%)
19 (29) 20 (31)
Cholesterol — mg/dl
Low‑density lipoprotein 114.1±57.7 122.3±63.0
Total 145.1±61.6 144.8±69.8
Anti‑PLA2R — U/ml
Median 409 413
Interquartile range 163–834 206–961
Anti‑PLA2R positive — no. (%)‡ 50 (77) 46 (71)
Serum albumin — g/dl
Median 2.5 2.5
Interquartile range 2.1–2.9 2.1–2.9
Serum creatinine — mg/dl 1.3±0.4 1.3±0.4
Urinary protein — g/24 hr
Median 8.9 8.9
Interquartile range 6.8–12.3 6.7–12.9
Urinary creatinine — g/24 hr 1.7±0.5 1.8±0.6
Creatinine clearance —  
ml/min/1.73 m2
84.9±29.8 87.4±34.4
Protein:creatinine§ 6.2±2.6 6.2±3.3
*  Plus–minus values are means ±SD. To convert values for cholesterol to milli‑
moles per liter, multiply by 0.02586. To convert values for creatinine to micro‑
moles per liter, multiply by 88.4. Anti‑PLA2R denotes anti–phospholipase A2 
receptor autoantibody.
†  The body‑mass index is the weight in kilograms divided by the square of the 
height in meters.
‡  Patients were considered to be anti‑PLA2R–positive if the value was more 
than 40 U per milliliter.
§  Protein and creatinine values were measured in milligrams.
Table 1. Characteristics of the Patients at Baseline.*
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Laboratory Outcomes and Quality of Life
In the 39 patients who were in remission 24 
months after the initiation of rituximab therapy, 
proteinuria had decreased from a geometric mean 
of 8.79 g per 24 hours at baseline to 0.30 g per 
24 hours at 24 months, and in the 13 patients who 
were in remission 24 months after the initiation 
of cyclosporine therapy, proteinuria had decreased 
Figure 1. Composite Outcome of Complete or Partial Remission at 12 and 24 Months.
Point estimates and two‑sided 95% confidence intervals are shown for the treatment effect, defined as the risk difference for complete 
or partial remission between groups in the intention‑to‑treat analysis. The noninferiority margin for rituximab as compared with cyclo‑
sporine was −15 percentage points. The lower end of the two‑sided 95% confidence interval of the risk difference in the secondary com‑
posite of complete remission or partial remission at 12 months was above −15 percentage points, and the P value for noninferiority of 
0.004 was significant, which met the prespecified alpha level of a P value of less than 0.0125 after Bonferroni correction. Per the statisti‑
cal analysis plan, no test for superiority was performed for the secondary outcome of complete or partial remission at 12 months. The 
lower limit of the two‑sided 95% confidence interval for the risk difference in the primary composite outcome of complete remission or 
partial remission at 24 months was above 0 percentage points; both the criterion for noninferiority and the criterion for superiority of 
rituximab were met at a P value of less than 0.001, which met the prespecified alpha levels specified for noninferiority (P<0.025) and su‑
periority (P<0.05). P values for noninferiority are one‑sided, and the P value for superiority is two‑sided.
−15 15 45300 60
Rituximab Superior to Cyclosporine
Rituximab Noninferior to Cyclosporine
End of treatment period
at 12 mo
End of follow-up at 24 mo
Cyclosporine
(N=65)
Risk Difference
(95% CI)
Rituximab
(N=65)Evaluation Time Point
40 (25 to 55)
−45 −30
  8 (−9 to 25)
P Value for
Noninferiority
34 (52)
13 (20)
39 (60)
39 (60)
0.004
<0.001
—   
<0.001
P Value for
Superiority
no. with complete or
partial remission (%) percentage points 
Noninferiority
margin
Time from Randomization Rituximab Cyclosporine Risk Difference (95% CI)
no. of patients with remission/total no. (%) percentage points
Intention-to-treat population
6 mo 23/65 (35) 32/65 (49) −14 (−31 to 3)
12 mo 39/65 (60) 34/65 (52) 8 (−9 to 25)
18 mo 40/65 (62) 15/65 (23) 38 (23 to 54)
24 mo 39/65 (60) 13/65 (20) 40 (25 to 55)
Per-protocol population
6 mo 22/63 (35) 32/63 (51) −16 (−33 to 1)
12 mo 38/63 (60) 33/63 (52) 8 (−9 to 25)
18 mo 39/63 (62) 15/63 (24) 38 (22 to 54)
24 mo 39/63 (62) 13/63 (21) 41 (26 to 57)
*  The intention‑to‑treat population included all the patients who underwent randomization, and the per‑protocol popula‑
tion included all the patients who received a full course of trial medications, defined as at least one completed 6‑month 
treatment cycle, according to the protocol. The primary outcome was the composite of complete or partial remission at 
24 months. The primary noninferiority analysis and the superiority analysis of the primary outcome at 24 months were 
performed in the intention‑to‑treat population, and an additional noninferiority analysis of the primary outcome at 24 
months was performed in the per‑protocol population. Because the widths of the 95% confidence intervals for second‑
ary outcomes were not adjusted for multiple comparisons, these intervals should not be used for inference about treat‑
ment effects.
Table 2. Composite Outcome of Complete or Partial Remission at 6 to 24 Months.*
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from 9.46 g per 24 hours to 1.02 g per 24 hours 
(between-group difference at 24 months, −0.72 
g per 24 hours; 95% CI, −0.86 to −0.47). Blood 
pressure remained stable during treatment with 
rituximab but increased with cyclosporine treat-
ment, with differences at 12 months of −10.7 
mm Hg (95% CI, −17.2 to −4.1) in the systolic 
blood pressure and −6.6 mm Hg (95% CI, −10.4 
to −2.7) in the diastolic blood pressure. There 
was little evidence of between-group differences 
at 18 and 24 months. The mean creatinine clear-
ance in patients in remission was higher in the 
rituximab group than in the cyclosporine group 
at all time points, with between-group differ-
ences of 26 ml per minute per 1.73 m2 (95% CI, 
17 to 35) at 12 months and of 18 ml per minute 
per 1.73 m2 (95% CI, 5 to 31) at 24 months. De-
tails are provided in Figures S8 and S9 and Ta-
bles S9 and S10 in the Supplementary Appendix.
The decline in anti-PLA2R antibody levels was 
faster and of greater magnitude and duration in 
anti-PLA2R–positive patients in remission in the 
rituximab group than in those in the cyclosporine 
group and was accompanied by a greater decline 
in proteinuria. The anti-THSD7A–positive patient 
who had been assigned to the rituximab group was 
anti-THSD7A–negative from 3 months onward and 
then had a partial remission at 9 months and a 
complete remission at 12 months, which was 
maintained until 24 months. Details are provided 
in Figure S10 and Tables S11 through S13 in the 
Supplementary Appendix.
Table S14 in the Supplementary Appendix 
presents selected quality-of-life subscales in pa-
tients with remission of proteinuria at 6, 12, and 
24 months. There was little evidence of between-
group differences, except in the symptom or prob-
lem list at 6 months and the mental health com-
posite at 12 months.
Adverse Events
The incidence of adverse events was similar in 
the rituximab group and the cyclosporine group 
(71% and 78% of patients, respectively). The in-
cidence of adverse events of grade 3 or higher 
was 52% in the rituximab group and 68% in the 
cyclosporine group, and the incidence of serious 
adverse events was 17% and 31%, respectively 
(Table 3). A total of seven patients (11%) discon-
tinued cyclosporine because of adverse events 
(Table S15 in the Supplementary Appendix). In-
creased serum creatinine levels and gastrointes-
tinal events were more common with cyclosporine, 
whereas pruritus and infusion-related reactions 
were more frequent with rituximab. End-stage 
renal disease developed in one patient in the cy-
closporine group. No cancers or deaths occurred 
during the trial. Tables S16 through S32 and 
Figure S11 in the Supplementary Appendix present 
additional analyses of efficacy and safety out-
comes.
Discussion
We found that rituximab was noninferior to cy-
closporine in inducing proteinuria remission at 
Figure 2. Time to Treatment Failure.
Shown are Kaplan–Meier estimates of the time to treatment failure. Patients 
were considered to have treatment failure if they had reduction in protein‑
uria of less than 25% from baseline at 6 months, had a relapse, had a pre‑
mature termination of the protocol‑specified treatment schedule before  
12 months because of disease activity or adverse event, used an immuno‑
suppressive medication other than the trial medication for the treatment  
of membranous nephropathy before 12 months, used any immunosuppres‑
sive medication for the treatment of membranous nephropathy after  
12 months and before 24 months, or did not meet the criteria for a com‑
plete or partial remission at 24 months. Patients who were lost to follow‑up 
at 24 months were considered to have had treatment failure unless they 
were found to have had a complete or partial remission at their 18‑month 
visit. A test of the proportional‑hazards assumption based on Schoenfeld 
residuals showed a P value of 0.06. A time‑by‑treatment interaction that 
was based on a cutoff at 1 year to distinguish between the treatment peri‑
od up to 12 months and the subsequent follow‑up from month 13 through 
month 24 was positive (ratio of hazard ratios, 0.22; 95% CI, 0.09 to 0.55; 
P = 0.001 for interaction), with hazard ratios of 0.68 (95% CI, 0.36 to 1.26) 
for the period up to 12 months and 0.15 (95% CI 0.07 to 0.30) for the peri‑
od between 13 and 24 months. After the inclusion of the interaction term, 
the overall test of the proportional‑hazards assumption was negative 
(P = 0.17).
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12 months and was superior in maintaining 
long-term proteinuria remission up to 24 months 
in patients with membranous nephropathy who 
were at high risk for progressive disease.7 The 
superiority of rituximab at 24 months appeared 
to be driven by the significantly lower incidence 
of relapse in the rituximab group than in the 
cyclosporine group during the observation peri-
Event Rituximab (N = 65) Cyclosporine (N = 65) P Value*
Patients Events Patients Events
no. (%)
no. of events (rate 
per 100 patients) no. (%)
no. of events (rate 
per 100 patients)
Any adverse event 46 (71) 179 (275) 51 (78) 218 (335) 0.31
Grade ≥3 11 (17) 14 (22) 23 (35) 27 (42) 0.02
Grade <3 44 (68) 165 (254) 45 (69) 191 (294) 0.85
Serious adverse event 11 (17) 13 (20) 20 (31) 22 (34) 0.06
Fatal 0 0 0 0 1.00
Nonfatal 11 (17) 13 (20) 20 (31) 22 (34) 0.06
Adverse event occurring in ≥4 patients
Hypertension 0 0 5 (8) 6 (9) 0.06
Hyperkalemia 1 (2) 1 (2) 4 (6) 12 (18) 0.37
Gastrointestinal pain 1 (2) 2 (3) 9 (14) 9 (14) 0.02
Gingival event 1 (2) 1 (2) 4 (6) 4 (6) 0.37
Nausea or vomiting 2 (3) 4 (6) 9 (14) 15 (23) 0.03
Chills 1 (2) 1 (2) 5 (8) 5 (8) 0.21
Edema 4 (6) 5 (8) 5 (8) 6 (9) 1.00
Fatigue 5 (8) 6 (9) 8 (12) 8 (12) 0.38
Influenza‑like symptoms 6 (9) 8 (12) 3 (5) 3 (5) 0.49
Infusion‑related reaction 16 (25) 22 (34) 0 0 <0.001
Gastrointestinal infection 4 (6) 4 (6) 4 (6) 4 (6) 1.00
Pneumonia 1 (2) 1 (2) 6 (9) 6 (9) 0.12
Other respiratory tract infection 9 (14) 12 (18) 9 (14) 10 (15) 1.00
Skin infection 4 (6) 5 (8) 0 0 0.12
Muscle cramps 6 (9) 9 (14) 4 (6) 5 (8) 0.74
Myalgia 4 (6) 4 (6) 6 (9) 8 (12) 0.74
Pain 2 (3) 3 (5) 4 (6) 7 (11) 0.68
Dizziness 2 (3) 3 (5) 4 (6) 5 (8) 0.68
Headache 4 (6) 5 (8) 7 (11) 8 (12) 0.34
Paresthesia or dysesthesia 2 (3) 2 (3) 4 (6) 5 (8) 0.68
Anxiety or depression 1 (2) 1 (2) 4 (6) 6 (9) 0.37
Increased creatinine level† 4 (6) 5 (8) 15 (23) 17 (26) 0.01
Cough 7 (11) 9 (14) 2 (3) 4 (6) 0.16
Dyspnea 2 (3) 2 (3) 3 (5) 3 (5) 1.00
Pruritus 7 (11) 8 (12) 0 0 0.01
*  P values are for the difference in proportions of patients having a specific type of event. P values were not adjusted for multiple comparisons.
†  End‑stage renal disease developed in one patient in the cyclosporine group.
Table 3. Adverse Events.
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od at months 13 to 24. The observed response at 
24 months was close to the percentage that had 
been assumed in the power analysis for ritux-
imab but was less than half the assumed per-
centage for cyclosporine. The lower-than-antici-
pated response in the cyclosporine group may be 
due to the inclusion of patients who had more 
severe proteinuria than did the patients in our 
previous trial.13 The decline in proteinuria was 
more pronounced in patients who had a com-
plete or partial remission with rituximab than in 
those in the cyclosporine group who had a com-
plete or partial remission, and 23 patients 
treated with rituximab had a complete remission 
at 24 months, as compared with none of the 
patients treated with cyclosporine — a finding 
that suggests more frequent and more sustained 
remissions with rituximab than with cyclospo-
rine. Remission of proteinuria is a recognized 
surrogate marker for long-term outcome in pa-
tients with membranous nephropathy.29 A recent 
study involving patients with membranous ne-
phropathy showed that the longer the remission, 
the greater the improvement in renal survival 
— a finding that emphasizes the value of partial 
remission and complete remission of proteinuria 
as surrogates for long-term outcome in patients 
with membranous nephropathy.30
Adverse events were common and similar in 
the two groups, but serious events were slightly 
less frequent with rituximab than with cyclospo-
rine — findings that are consonant with recent 
data.14 Renal function was worse after cyclospo-
rine therapy than after rituximab therapy; the 
reduction in renal function after cyclosporine 
use was only partially explained by reversible 
hemodynamic effects during active treatment. 
Residual kidney dysfunction persisted after the 
discontinuation of cyclosporine therapy, which 
suggests that chronic cyclosporine nephrotoxic-
ity, a known negative effect of cyclosporine, may 
have played a role.
Finally, between-group differences in com-
plete or partial remission appeared to be more 
pronounced in women than in men — a finding 
that is probably explained by confounding due to 
baseline imbalances in anti-PLA2R levels. Anti-
body suppression occurred earlier and was more 
complete and sustained, persisting throughout 
the second year of the trial, in anti-PLA2R–posi-
tive patients who were treated with rituximab 
than in anti-PLA2R–positive patients who were 
treated with cyclosporine. The immunologic re-
sponse to rituximab preceded the clinical re-
sponse, a pattern that consistently emerges from 
the trials in membranous nephropathy that have 
shown the dynamics of anti-PLA2R antibody 
levels in relation to clinical variables.4,6,20 Exten-
sive immunologic damage requires prolonged 
podocyte remodeling before the architecture and 
function of the glomerular filtration barrier are 
restored, and such damage may explain the de-
lay between immunologic response and decline 
in proteinuria.
The infrequent intravenous administration of 
rituximab, as compared with twice-daily oral 
cyclosporine, resulted in better adherence to 
therapy. Although the initial treatment costs are 
substantially higher with rituximab than with 
cyclosporine, this factor needs to be weighed 
against the prolonged benefits, higher quality of 
remission, better preservation of kidney func-
tion, and lower incidence of relapse with ritux-
imab. A recent analysis of the cost-effectiveness 
of treating membranous nephropathy with alter-
nating glucocorticoids and cyclophosphamide, 
as compared with rituximab, showed that despite 
initially higher costs of rituximab, the overall cost 
was lower because of the prolonged remission 
that was obtained with rituximab.31 The limited 
overall incidence of remission of 50 to 60% may 
be an underestimation of the true effect of ritux-
imab since, as shown in other studies involving 
patients who had a response to rituximab, pro-
teinuria decline is gradual and the nadir may not 
be reached until 36 months after the initiation 
of treatment.20
Given the complex immunosuppressive treat-
ment regimens and the cost involved, it did not 
seem feasible in our trial for patients and thera-
pists to be unaware of the treatment assignments, 
which could have affected the treatment of the 
patient and the assessment of disease status. 
However, the definition of the primary outcome 
was based on objective laboratory values mea-
sured by personnel who were unaware of group 
assignments; thus, lack of blinding seems to be 
an unlikely explanation for the magnitude of the 
observed between-group difference at 24 months. 
We cannot rule out the possibility that longer 
treatment or follow-up of patients who did not 
have a decrease in proteinuria of at least 25% at 
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6 months might eventually have increased the 
percentage of patients with a response. However, 
in view of the symmetric pattern that was observed 
at 6 months in patients assigned to the ritux-
imab group and those assigned to the cyclospo-
rine group, we speculate that it is unlikely that a 
hypothetical change in protocol, with longer treat-
ment and follow-up for patients with a decrease in 
proteinuria of less than 25% at 6 months, would 
have changed the overall conclusions.
Another limitation of our trial is that labora-
tory outcomes and quality of life were system-
atically recorded only up to the occurrence of 
treatment failure. Therefore, those outcomes were 
analyzed only in patients who had remission at 
each time point. Although that approach allowed 
comparisons of the quality of remission between 
groups, the design did not allow us to explore 
the effect of the originally assigned treatment 
strategy on laboratory outcomes and quality of life 
in the intention-to-treat population. It is possible 
that between-group differences in KDQOL-SF 
quality-of-life scores in the intention-to-treat 
population would have been considerably more 
pronounced, but studies involving patients with 
membranous nephropathy that could confirm 
or refute this hypothesis have been limited. The 
observed modest between-group differences in 
the KDQOL-SF mental health composite in pa-
tients who were in remission at 12 months, if 
confirmed, might relate to differences in per-
ceived intrusiveness or effect of the two treat-
ments on daily life, but their clinical relevance 
remains unclear.
Since the CD19+ B-cell counts remained low at 
12 months, we cannot rule out a residual thera-
peutic effect of rituximab beyond this time peri-
od. However, in our two previous studies, CD19+ 
B-cell counts at 12 months showed no relation 
to proteinuria response.21,22 We also acknowledge 
that using a lower cutoff value for the ELISA, 
performing Western blot, or detecting anti-PLA2R 
antibodies by means of serum immunofluores-
cence could have resulted in more patients who 
were considered to be PLA2R–positive.32
In conclusion, rituximab was noninferior to 
cyclosporine in inducing proteinuria remission 
at 12 months and was superior in maintaining 
long-term proteinuria remission up to 24 months 
in patients with membranous nephropathy who 
were at high risk for progressive disease.
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